Taiwan FDA registration b748b8f112fad3756c9c3edb4306233d
"Haifong Biomedical" Rivaroxaban correction solution group
TW: “海奉生物醫學” Rivaroxaban校正液組
Taiwan·Risk Class 2·HYPHEN BioMed·Registered Feb 23, 2021 – Feb 23, 2026ExpiredRegistration details
- Analysis ID
- b748b8f112fad3756c9c3edb4306233d
- Customs Code
- DHA05603436301
Company information
- Manufacturer
- HYPHEN BioMed
- Manufacturer Country
- France
- Authorized Representative
- SYSMEX TAIWAN CO., LTD.
Product details
- Intended Use
- This product is lyophilized human plasma containing different concentrations of Rivaroxaban for correction of Rivaroxaban measurement.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1150 Calibrated Products
- Import Information
- QMS/QSD;; 輸入
Dates and status
- Registration Date
- Feb 23, 2021
- Expiry Date
- Feb 23, 2026
About this record
Access comprehensive regulatory information for "Haifong Biomedical" Rivaroxaban correction solution group in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number b748b8f112fad3756c9c3edb4306233d and manufactured by HYPHEN BioMed. The authorized representative in Taiwan is SYSMEX TAIWAN CO., LTD..
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices